Knowledge about breast carcinogenesis has accumulated during the last decades but has barely been translated into strategies for early detection or prevention of this common disease. Changes in DNA methylation have been recognized as one of the most common molecular alterations in human neoplasia and hypermethylation of gene-promoter regions is being revealed as one of the most frequent mechanisms of loss of gene function. The heritability of methylation states and the secondary nature of the decision to attract or exclude methylation support the idea that DNA methylation is adapted for a specific cellular memory. According to Hanahan and Weinberg, there are six novel capabilities a cell has to acquire to become a cancer cell: limitless replicative potential, self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, sustained angiogenesis and tissue invasion and metastasis. This review highlights how DNA-methylation contributes to these features and offers suggestions about how these changes could be prevented, reverted or used as a 'tag' for early detection of breast cancer or, preferably, for detection of premalignant changes.
Introduction
Each year more than 180 000 women in the US are diagnosed with breast cancer, the most common cancer among women in this country. If current breast cancer rates remain constant, a woman born today has a one in 10 chance of developing breast cancer (Eifel et al., 2001; Howe et al., 2001) . Each year, 44 000 women die of breast cancer, making it the second leading cause of cancer deaths among American women, after lung cancer, and the leading cause of death among women aged 40 to 55 years.
Decades of research have led to a substantial understanding of the factors involved in the development of breast cancer. All these factors cause or are at least associated with development of breast cancer and lead to a 'new type of tissue' (neoplasm) characterized by a variety of genetic lesions including gene amplifications, gene deletions, point mutations, loss of heterozygosity, chromosomal rearrangements, and overall aneuploidy.
Besides the above mentioned well known genetic alterations, epigenetic alterations are among the most common molecular alterations in human neoplasia Jones, 1996; Jones and Laird, 1999) . Epigenetic changes differ from genetic changes mainly in that they occur at a higher frequency than genetic changes, are reversible upon treatment with pharmacological agents and occur at defined regions in a gene. Epigenetics describes a trait that is heritable, yet not based upon a change in primary DNA sequence. DNA methylation is one well known epigenetic-mechanism and it has become clear in recent years that there is a synergy between genetic and epigenetic changes and that Knudson's two-hit hypothesis has to be revised: instead of two possibilities (loss of heterozygosity or homozygous deletion), a third possibility -transcriptional silencing by DNA methylation of promoters -can disable tumor-suppressor genes (Jones and Laird, 1999) .
Cytosines are methylated in the human genome mostly when located 5' to a guanosine. These CpG nucleotides have been severely depleted in the vertebrate genome to about 20% of the predicted frequency and most CpG dinucleotides (over 70%) are methylated. However, in small stretches of DNA termed CpG islands, which are about 500 -2000 bp in length (Jones and Takai, 2001; Takai and Jones, 2002) , the CpG dinucleotide occurs at near the expected frequency and these areas are frequently located in and around the transcription-start sites of approximately half of human genes. It has been increasingly recognized over the past 4 -5 years that the CpG islands of a large number of genes, which are mostly unmethylated in normal tissues, are methylated to varying degrees in human cancers, including breast cancer (Yang et al., 2001a) . The post-synthetic covalent addition of a methyl group to cytosine is mediated by the three known active DNA cytosine methyltransferase (DNMT1, 3a and 3b) (Robertson et al., 1999) .
When DNA containing a symmetrically methylated CpG dinucleotide is replicated, the result is two double-stranded DNA molecules, each containing a methylated CpG dinucleotide on the parental strand but containing an unmethylated CpG dinucleotide on the newly synthesized strand. The methylated state of the site on the parent molecule is maintained in the daughter molecules when a maintenance methyltransferase recognizes the hemimethylated site and methylates the unmethylated cytosine, restoring the symmetrically methylated CpG dinucleotide pair. DNMT1 is mainly responsible for maintenance of DNA methylation, whereas DNMT3a and DNMT3b have been shown to methylate hemimethylated and unmethylated DNA with equal efficiencies (Okano et al., 1999) . Overexpression of DNMT1 as well as the DNMT3 mRNAs has been reported in human tumors (Mizuno et al., 2001; Robertson et al., 1999) , but this phenomenon is probably only partially responsible for the observed methylation changes. Compared to normal tissue, DNA from breast carcinomas is generally hypomethylated (Soares et al., 1999) ; DNMTs appear to be upregulated in tumors when RNA levels are normalized using b-actin or RNA pol II large subunit, but not when RNA levels are normalized with proliferation associated genes, such as histone H4 or PCNA (Eads et al., 1999) . In this study, using colorectal tumors, neither the frequency nor the extent of CpG island hypermethylation in individual tumors correlated with mRNA expression of any of the three DNA methyltransferases. In hepatocellular carcinoma, hypomethylation was also associated with upregulation of DNMT expression . Therefore, up-regulation of DNMTs mRNAs may simply be a result of increased cell proliferation in cancer. Although it appears that different DNMT enzymes have distinct sequences targeted for methylation (Hsieh, 1999; Okano et al., 1999) , this fact does not completely explain the significant variety of methylation patterns in tumors.
These epigenetic markers on DNA can be copied after DNA synthesis, resulting in heritable changes in chromatin structure. The reciprocal relationship between the density of methylated cytosine residues and the transcriptional activity of a gene has been widely documented. It should be emphasized, however, that this inverse correlation has been demonstrated conclusively only for methylation in the promoter regions and not in the transcribed parts of a gene (Jones, 1999) . Several tumor-suppressor genes contain CpG islands in their promoters, and many of them show evidence of methylation silencing. After changes associated with histone deacetylation have occurred and after these CpG islands have become methylated, the relevant genes become irrevocably silent.
A woman's risk of developing breast cancer is increased if she has a family history of the disease. The largest re-analysis of individual data from 52 epidemiological studies so far completed reported that 12% of women with breast cancer had one affected relative and 1% had two or more (Collaborative Group on Hormonal Factors in Breast Cancer, 2001) .
Therefore the genesis of most breast cancers cannot be explained by heritage. Age as well as duration of exposure to endogenous or exogenous steroid hormone levels might be one of the best defined risk factors for breast cancer. Breast cancer is uncommon among women younger than 30 years of age but the incidence increases sharply with age. The rate of increase in breast cancer incidence continues throughout life but slows somewhat between ages 45 and 50 years. This finding strongly suggests the involvement of reproductive hormones in breast cancer etiology, because nonhormone-dependent cancers do not exhibit this change in slope of the incidence curve around the time of menopause (Pike et al., 1993) . Several reproductive factors that alter estrogen status effect risk of breast cancer: early age at menarche and late age at menopause are associated with increased risk of breast cancer. After menopause, adipose tissue is the major source of estrogen, and obese postmenopausal women have both higher levels of endogenous estrogen and a higher risk of breast cancer (Harris et al., 1992; Huang et al., 1997a) . Postmenopausal hormone use increases the breast cancer risk depending on the duration of use and whether estrogen alone or estrogen in combination with progestin is taken (Ross et al., 2000) . On the other hand, hormonal manipulations, such as administration of antiestrogens (e.g., tamoxifen), are useful in the treatment of breast cancer and might reduce breast cancer incidence in high-risk women (Fisher et al., 1998) . Based on this knowledge a model connecting epidemiologic knowledge can be built which incorporates recently discovered epigenetic changes in breast cancer.
A woman's age might be the driving force for the accumulation of mutational load, telomere dysfunction and increased epigenetic gene silencing. Exposure to growth factors like estrogen increases the likelihood of occurrence of these changes in breast epithelial stem cells as well as the propagation of these changes by enabling the cells to divide. Growth factors may not only act directly on epithelial cells but also indirectly via the stromal microenvironment in which the tumor cells develop and may profoundly influence many steps of tumor progression. In various experimental tumor models, the microenvironment affects the efficiency of tumor formation, the rate of tumor growth, the extent of invasiveness, and the ability of tumor cells to metastasize. In carcinomas, the influences of the microenvironment are mediated, in large part, by paracrine signaling between epithelial tumor cells and neighboring stromal fibroblasts ).
DNA methylation and the establishment of six novel capabilities towards breast carcinogenesis
Recently Hanahan and Weinberg (2000) provided an excellent overview of alterations in cell physiology that collectively define malignant growth. The six new capabilities, that a cell has to acquire to become malignant are: (1) limitless replicative potential, (2) self-sufficiency in growth signals, (3) insensitivity to growth-inhibitory signals, (4) evasion of programmed cell death, (5) sustained angiogenesis and (6) tissue invasion and metastasis. Despite the fact that many genes mentioned below might have overlapping functions in different pathways, we use this classification to highlight how DNA methylation may contribute to breast carcinogenesis (Figure 1 ).
(1) Limitless replicative potential Senescence and genomic integrity are thought to be important barriers to the development of malignant lesions. Human fibroblasts undergo a limited number of cell divisions before entering an irreversible arrest, called senescence. In contrast, human mammary epithelial cells (HMECs) in culture exhibit an initial growth phase that is followed by a transient growth plateau (termed selection or M0), from which proliferative cells emerge to undergo further population doublings, before entering a second growth plateau (termed postselection, agonescence or M1). Cells emerging from this stage enter a telomere-based crisis-like state (Romanov et al., 2001) . p16
INK4A , one of the most commonly inactivated tumor suppressor genes in human cancer (Sherr, 1996) , is a cyclindependent kinase inhibitor that regulates progression through the G1 phase of the cell cycle by binding and inhibiting cyclin-dependent kinases 4 and 6 (Jiang et al., 1998) thus inhibiting Rb phosphorylation. In early passage HMECs, p16
Ink4A increases as HMECs reach M0, and this is paralleled by a decrease in the level of Rb . HMECs that emerge from the first plateau lose expression of p16
INK4A protein, and this correlates with a progressive, region-specific de novo methylation of the p16 CpG island (Brenner et al., 1998; Foster et al., 1998; Huschtscha et al., 1998;  Figure 1 View of breast carcinogenesis from a DNA methylation standpoint. DNA-methylation of certain genes and therefore irrevocably silencing them, enables some cells to acquire new capabilities needed for tumorigenesis. Prolonged exposure to growth promoting substances like estradiol, which exerts direct effects on epithelial cells or indirect effects via stromal cells, allows cells to propagate heritable changes like DNA-methylation. Cells which accumulated DNA-methylation at various loci as a function of time (age) and as a function of exposure to growth factors (e.g. estrogens), have gained all six novel capabilities needed to be a tumor cell due to the fact that 'defense strategies' have irrevocably switched off by DNA-methylation Wong et al., 1999) . These results raise the question of the mechanism responsible for de novo methylation of this region and whether DNA methylation is responsible for p16 INK4A gene silencing. Recently it has been demonstrated that either Ets1 and Ets2 (through an Ets-binding site) (Ohtani et al., 2001) , or class A basic HLH proteins (Pagliuca et al., 2000) (by activating E-boxes within the p16 INK4A promoter) can activate p16
INK4A gene expression and that Id1 represses p16 expression by either interfering with basic HLH proteins or Ets factors (Alani et al., 2001; Ohtani et al., 2001) . Id genes can immortalize various types of cells, and Id1 overexpression causes more aggressive phenotypes of breast cancer and regulates steroid-hormone-responsive growth of breast cancer cells (referenced in Norton, 2000) . Although there is a striking chronological association between Id-1 regulation of cellular senescence through transcriptional repression of p16
INK4A (Alani et al., 2001 ) and p16
INK4A promoter methylation Wong et al., 1999) , it is unclear whether Id-1 directly or indirectly causes methylation at this specific region or whether Id-1 suppresses p16
INK4A expression in the absence of DNA methylation.
The fact that treatment with demethylating agents in vivo as well as in vitro causes a robust re-expression of p16 in large varieties of tumors (Bender et al., 1998) as well as in hTERT-immortalized cells (Farwell et al., 2000) supports the hypothesis that methylation of the p16 promoter may be a very important mechanism for permanent silencing of the p16 INK4A gene. Wong et al. (1999) have studied the methylation status of seven CpG sites in the p16 CpG island on individual DNA molecules by sequencing PCR clones of bisulfite-treated genomic DNA. They found that this island was initially methylated at a subset of sites in three discrete regions in association with p16 transcriptional repression and escape from M0 growth arrest. Methylation gradually increased in density with continued passage and spread to sites in adjacent regions. Noteworthy, the E-box motif of the p16
INK4A
promoter lies about one nucleosome distance upstream of the first region, whereas regions 1, 2 and 3 are also separated by approximately one nucleosome distance. Figure 2 Preventive, therapeutic and diagnostic possibilities using DNA methylation as a target. Changes in the chromatin structure of genes not activated might serve as a substrate for DNA-methylation. Exposure to carcinogens can not be handled properly because genes needed for this purpose cannot be expressed any more. Accumulation of these genes irrevocably silenced may lead to cancer. Green numbers: Mechanisms of prevention or reversal of DNA methylation (most of them have not been studied extensively in breast cancer). (1) Challenging breast epithelial stem cells early in life (analogous to pregnancy at young age or to a pregnancy complicated by pre-eclampsia) might prevent methylation of important cell-death pathways and thereby giving these cells the chance to recall efficient patterns of genes to adequately handle exposure to carcinogens. (2) HDAC inhibitors -applied systemically or retrograde intraductally -might prove to be efficient to prevent DNA methylation and hence irreversible silencing. (3) After DNA methylation of certain genes has already been established, demethylating agents might revert this process. (4) An established cancer might be treated with demethylating agents alone or in combination with biological response modifiers as outlined recently (Widschwendter and Jones, 2002) . Red numbers: Diagnostic possibilities in breast cancer using DNA methylation. (5) Examining DNAmethylation of certain genes in breast nipple fluid might be used for early detection of premalignant lesions or non-invasive cancer. (6) Chemopreventive strategies might be monitored by DNA methylation (surrogate endpoint biomarker) in breast nipple fluid. (7) Evidence for systemic disease might be gained due to analysis of DNA methylation in patients' blood and might serve as a predictive marker. Relapse of disease might be detected early by means of studying DNA methylation in patients' blood and therapies might be monitored using DNA methylation as a tumor marker. It has to be stressed that for different purposes ((5) to (7)), different combinations of various genes might prove to be useful The overall maintenance methylating activity in fibroblasts is greatly decreased during cellular senescence but is strikingly elevated in immortalized cells (Lopatina et al., 2002) . Detailed analyses demonstrated that the major maintenance methyltransferase, DNMT1, declined steadily in activity with cellular senescence and immortalization. However, DNMT3B, which has significant de novo methylating activity, increased markedly in activity in aging and immortalized cells (Lopatina et al., 2002) . These studies indicated that reduced genome-wide methylation in aging cells (Wilson and Jones, 1983) (Kiyono et al., 1998) . Although telomerase, which maintains the integrity of chromosome ends, is downregulated as cells differentiate leading to attrition of chromosomal termini and ultimate replicative senescence, it is up-regulated in most cancer cells which show no net loss of average telomere length. The mRNA level of the catalytic component of telomerase, hTERT, is the major determinant of telomerase activity but little is known about control of hTERT transcription. Recently Tollefsbol and Andrews (2001) have proposed mechanisms whereby cytosine methylation may alter the binding of activators such as c-Myc or repressors such as WT1 which interact with the hTERT gene regulatory region to modulate telomerase activity in aging cells and tumorigenesis. hTERT is methylated in some breast cancer cell lines (Devereux et al., 1999) , but no specific methylation patterns at certain CpG sites or regions of the hTERT promoter emerged that correlated with expression in all of the diverse cell lines examined (Devereux et al., 1999) . As outlined in the Introduction, exposure to estrogen is a major risk factor for breast cancer. It has been shown that estrogen is also able to activate telomerase via direct and indirect effects on hTERT promoter (Kyo et al., 1999) in a breast cancer cell line.
Besides p16 INK4A , the retinoblastoma protein-interacting zinc finger gene (RIZ1), which is a tumor suppressor gene and a member of a nuclear histone/ protein methyltransferase superfamily, can affect Rb. RIZ1 inactivation is commonly found in many types of human cancers and occurs through loss of mRNA expression, frameshift mutation, chromosomal deletion, and missense mutation. It has been shown that loss of RIZ1 mRNA in human cancers is associated with DNA methylation of its promoter CpG island . Methylation of the RIZ1 promoter was found in 44% of breast cancer specimens and strongly correlated with lost or decreased RIZ1 mRNA expression. Treatment with the methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) activated RIZ1 mRNA expression in cancer cells . Additional evidence has suggested that RIZ1 protein may be a specific effector of estrogen action downstream of the hormone-receptor interaction, presumably involved in proliferation control (Abbondanza et al., 2000) .
D-type cyclins (cyclins D1, D2, and D3) are involved in regulation of transition from G1 to S during the cell cycle. Cyclin D2 is unique among the three D-type cyclins, as its expression is significantly upregulated under conditions of growth arrest in phenotypically normal human fibroblasts. Ectopic overexpression of cyclin D2 effectively blocked cell cycle progression (Meyyappan et al., 1998) . Hypermethylation of the CpG island in the cyclin D2 promoter was detected by methylation-specific PCR in nearly half of the breast cancers and was associated with silencing of cyclin D2 gene expression. Promoter hypermethylation was also detected in ductal carcinoma in situ, suggesting that loss of cyclin D2 expression is an early event in tumorigenesis (Evron et al., 2001a) . A variety of other genes are known to be induced upon senescence in addition to p16. Retinoids are important cellular dietary factors that regulate differentiation and cellular growth and serve as ligands for specific nuclear receptors, the retinoic acid receptors (RARs) (Minucci and Pelicci, 1999) . Ligand-activated receptors regulate gene transcription through target retinoic acid-responsive elements (RAREs) found in promoter regions. Transcription of the RAR-b2 gene is induced by retinoic acid and RAR-b is able to repress AP1, a condition which might be incompatible with tumor progression (reviewed in Altucci and Gronemeyer, 2001 ). In P19 embryonal carcinoma cells, retinoic acid markedly increases nuclease sensitivity within the promoter, including a site near the RARE to which the nuclear receptor retinoid X receptor (RXR)-RAR heterodimer binds. These changes became undetectable upon removal of RA, which coincides with the extinction of transcription (Bhattacharyya et al., 1997) . In the absence of agonists, corepressor complexes bind to the RAR-RXR heterodimer. This complex attracts histone deacetylases to an area surrounding RAREs to remove acetyl groups from nucleosomal histones, resulting in chromatin condensation and gene silencing (reviewed in Altucci and Gronemeyer, 2001 ). This transcriptionally silent chromatin might serve as a de novo methylation target (Bird, 2002) . Analyses with receptor-selective ligands and an antagonist showed that increase in restriction site accessibility correlates with transcriptional activation, which parallels the RA-induced in vivo footprint of the promoter. It has been demonstrated that most tumor cells show a loss of RAR-b expression, but that RAR-a and -g as well as retinoid X receptor b were variably expressed in both normal and cancerous breast tissue and cells (Widschwendter et al., 1995 (Widschwendter et al., , 1997 Xu et al., 1997) . RAR-b gene expression is induced both by retinoic acid and by fenretinide in normal cells, but tumor cells fail to respond to either. In contrast, RAR-b expression increases with serial passage in senescing cells Swisshelm et al., 1994) . RAR-b promoter methylation has been demonstrated to be an important mechanism causing suppression of the RAR-b2 message (Arapshian et al., 2000; Bovenzi et al., 1999; Sirchia et al., 2000; Widschwendter et al., 2000) in breast cancer. No RAR-b2 methylation was observed in normal breast tissue nor in mortal or immortal human mammary epithelial cells (Sirchia et al, 2000) . Alterations of the chromatin structure mediated by low intracellular levels of retinoic acid might precede DNA methylation at the RAR-b2 promoter (Sirchia et al., 2000) . Indeed, Rexer et al. (2001) have found that normal breast epithileum contains an enzyme, aldehyde dehydrogenase 6, that is capable of synthesizing retinoic acid from retinal and retinol. Expression of this enzyme is lost in breast cancer, explaining the defect of retinoic acid biosynthesis in these cells.
Together, this evidence might explain the chemopreventive potentials of retinoids: exposure to retinoic acid in cells that have lost their own ability to synthesize this ligand might activate the RAR-bRARE. Beside tumor suppressive effects mediated by RAR-b (Lotan et al., 1995) , this scenario prevents chromatin condensation at this region which would cause DNA methylation and irreversible suppression of the RAR-b.
Very recently, Di Croce et al. (2002) report an alternative mechanism of RAR-b methylation. In acute promyelocytic leukemias, PML-RAR acts as an oncogene and induces hypermethylation of the RARbRARE by recruiting DNA methyltransferases to this promoter. Retinoic acid treatment induces promoter demethylation, gene re-expression, and reversion of the transformed phenotype.
Another gene associated with senescence is mac25 (IGFBP-rP1), Insulin-like Growth Factor Binding Protein-related Protein-1). This gene was selected by differential display of mRNA in a search for genes overexpressed in senescent human mammary epithelial cells (Swisshelm et al., 1995) . Mac25 accumulates in senescent normal mammary epithelial cells but is absent or low in breast cancer cell lines and tissue (Landberg et al., 2001; Swisshelm et al., 1995) . In prostate cancer it was demonstrated that IGFBP-rP1/ mac25 alters cell cycle kinetics by delaying G1 progression and was associated with induction of apoptosis (Sprenger et al., 2002) . In the breast, strong IGFBP-rP1/mac25 staining was observed in luminal epithelial cells of normal lobules and ducts, in apocrine cells of cysts and fibroadenomas. Moderate to weak protein expression was found in hyperplastic and DCIS cells, but no specific staining was detected in invasive carcinoma cells (Burger et al., 1998) . Low IGFBP-rP1/ mac25 was associated with high cyclin E protein content, retinoblastoma protein (pRb) inactivation, low bcl-2 protein, poorly differentiated tumors and higher stage. There was a significantly impaired prognosis for patients with low IGFBP-rP1/mac25 protein tumors (Landberg et al., 2001) . Treatment with retinoids increases IGFBP-rP1/mac25 in normal mammary epithelial cells but not in tumor cells. It was proposed that IGFBP-rP1/mac25 expression may be regulated by RAR-b and represent one of the downstream genes on the RAR-b senescence pathway (Swisshelm et al., 1995) . Although there is no direct evidence that methylation causes silencing of IGFBPrP1/mac25 in breast cancer, restriction landmark genomic scanning for methylation has demonstrated that IGFBP-rP1/mac25 methylation and subsequent suppression of this gene was shown to be involved in murine SV40T/t antigen-induced hepatocarcinogenesis (Komatsu et al., 2000) .
Using a cDNA microarray approach, Perou et al. (1999) identified a cluster of interferon (IFN)-regulated genes (STAT-1, etc.) highly expressed in normal human mammary epithelial cells under three circumstances: addition of interferon, senescence and confluence. The latter two suggest that there may be circumstances that activate expression of these genes other than the presence of interferon. They also showed that this entire cluster of IFN-regulated genes was highly expressed in some of the tumors, moderately expressed in others and apparently silent in others (Perou et al., 1999) . A recent paper (Liang et al., 2002) used high density oligonucleotide gene expression microarrays to examine the effects of 5-aza-CdR treatment on a human bladder tumor cell line. Treatment with this demethylating agent showed 60 genes to be induced more than fourfold. Half of these genes belonged to the interferon signaling pathway and some also play important roles in breast carcinogenesis. Alterations of IL6 expression are associated with pathogenesis in breast cancer (Basolo et al., 1993) and the repression of IL6 is associated with hypermethylation (Armenante et al., 1999) . Expression of the intercellular adhesion molecule-1 (ICAM-1) is associated with good prognosis and might serve as a suppressor of tumor progression (Ogawa et al., 1998) . Despite the lack of direct proof, it was suggested that methylation of CpG islands may play a role in the downregulation of ICAM-1 (Arnold et al., 2001) . Elafin is an elastase inhibitor, constitutively expressed in normal mammary epithelial cells, but downregulated in most tumor cell lines (Zhang et al., 1995) . Manganese-containing superoxide dismutase functions as a tumor suppressor gene in breast cancer (Li et al., 2001a) and it is silenced by DNA methylation of the 5'-CpG island (Huang et al., 1997b) .
The interferon-g response has been postulated to be part of the endogenous tumor surveillance system. At the cellular level, IFN-g mediates activation of an antiviral state and causes cell growth arrest in the G 1 phase of the cell cycle. The biological effects of IFN-g are mediated through a heterodimeric transmembrane receptor which is capable of activating the Janus kinase (JAK)-STAT pathway, leading to tyrosine phosphorylation of the STAT1a protein (Stark et al., 1998) . STAT-1 plays an important role in growth arrest, in promoting apoptosis and is implicated as a tumor suppressor. Beside IFN-g, induction and activation of STAT-1 is mediated by retinoic acid via the RAR-b signaling pathways in breast cancer cells (Shang et al., 1999) . Inhibition of DNMTs stimulates the expression of STAT1, 2 and 3 in colon tumor cells (Karpf et al., 1999) . It has been demonstrated that STAT1 acts in concert with the BRCA1 tumor suppressor to differentially activate transcription of a subset of IFN-g target genes (Ouchi et al., 2000) . Induction of the cyclin-dependent kinase inhibitor p21 WAF1 was synergistically activated by BRCA1, whereas the IRF-1 gene was unaffected. BRCA1 promoter hypermethylation has been described to be present in about 13% of unselected primary breast carcinomas (Esteller et al., 2000) and these tumors may mimick the gene expression profiles found in breast cancers from patients with BRCA1 germline mutations (Hedenfalk et al., 2001) . The sis-inducible element (SIE)-1, a STAT responsive element located upstream of the p21
WAF1
CpG island was shown to be completely methylated in rhabdomyosarcomas. Using electrophoretic mobility shift assays methylation within SIE-1 significantly inhibited binding of activated STAT1 and abrogated STAT-mediated transcription activation in response to IFN-g. However demethylation at SIE-1 reactivated p21 WAF1 expression and restored the responsiveness to IFN-g . Another protein shown to interact with BRCA1 is SRBC (serum deprivation response factor (sdr)-related gene product that binds to c-kinase), which was isolated in a yeast two-hybrid screening with BRCA1 as the probe (Xu et al., 2001) . Although the function of SRBC is not yet clear, it has been shown that suppression of this gene is associated with hypermethylation of CpG dinucleotides in its promoter region (Xu et al., 2001) .
In addition to an active telomerase and presence of H-ras, SV40 large T antigen is known to be necessary to transform human mammary epithelial cells into human breast cancer cells . p53 inhibition -achieved by SV40 large T antigen -was required for the transformation of these cells. Inactivation of p53 by mutations is found in 20% of breast cancers (Pharoah et al., 1999) . Hypermethylation in the p53 promoter region is an alternative pathway to tumorigenesis where there is no p53 gene mutation (Kang et al., 2001) . About 60% of tumors showed neither methylation nor p53 mutation (Kang et al., 2001) . DNA damage leads to stabilization of p53, which is required for maintenance of the G2 arrest through the transactivation of the p21 and 14-3-3s genes. 14-3-3s is required to sequester cdc2-cyclinB1 complexes in the cytoplasm, whereas p21 may prevent any cdc2-cyclin B1 that enters the nucleus from becoming activated (Chan et al., 1999) . Hypermethylation of 14-3-3s was detected in more than 90% of breast cancers and was associated with lack of gene expression . Interestingly, beside invasive breast cancers, methylation of 14-3-3s was detected in 83% of ductal carcinoma in situ and 38% of atypical hyperplasias, but none of the hyperplasias without atypia showed hypermethylation (Umbricht et al., 2001) . Interestingly, patients with breast cancer showed 14-3-3s hypermethylation in normal adjacent breast epithelium as well, whereas epithelium from normal breasts contained unmethylated 14-3-3s, irrespective of age (Umbricht et al., 2001) .
The polycyclic aromatic hydrocarbon 7,12-dimethylbenz anthracene (DMBA) is a very potent inducer of mammary tumors in mice (Mehta, 2000) . DMBA induces NF-kB and increases c-myc levels in HMECs very early, occurring prior to malignant transformation (Kim et al., 2000) . c-myc may be one of the transcription factors necessary for induction of telomerase (Tollefsbol and Andrews, 2001) as outlined above. Glutathione S-transferases (GSTs) are a superfamily of genes, responsible for the detoxification of xenobiotics. GSTP1 null mice demonstrated an increased skin tumorigenesis after topical application of DMBA (Henderson et al., 1998) . MSP-based studies demonstrated that GSTP1 promoter methylation is associated with gene inactivation in about 30% of primary breast carcinomas (Esteller et al., 1998) . The GSTP1 CpG island is hypermethylated in ER positive, GSTP1 non-expressing cell lines but is undermethylated in ER negative, GSTP1 expressing cell lines (Jhaveri and Morrow, 1998).
(2) Self-sufficiency in growth signals Breast cancer can be divided into hormone responsive and non-responsive tumors. Hormone (or estrogen) responsive tumors can be controlled by the use of antiestrogens. A hormone independent tumor has acquired capabilities which enables it to grow in the absence of estrogen.
Estradiol is obligatory for normal development of the female breast as well as for induction and progression of mammary carcinoma. Most of the effects of estradiol are mediated by estrogen receptors (ERs). An excellent review by Nilsson et al. (2001) has highlighted the roles of ERs in the breast: There are two distinct and functional ERs, called ERa and ERb (Enmark et al., 1997; Green et al., 1986; Kuiper et al., 1996) . During pubertal growth and during the estrous cycle, the majority of proliferating cells both in terminal end buds and ducts are ERa negative (Clarke et al., 1997a,b; Zeps et al., 1998) . Induction of the progesterone receptor (PR) by estradiol does occur in ERa containing cells, and this induction occurs at much lower plasma levels of estradiol than are required for epithelial cell proliferation (Clarke et al., 1997b) . These observations have led to the concept (Wiesen et al., 1999) of two distinct types of responses to estradiol in the breast: (1) an indirect action in the mammary epithelium which occurs via ER-containing stromal cells and (2) a direct effect on ERa containing cells that occurs at low estradiol concentrations and results in induction of PR and differentiation of the epithelium.
Approximately 60% of proliferating cells in the mammary gland contain neither ERa nor ERb (Saji et al., 2000) . This observation raises the question of why ERa containing breast epithelial cells do not divide but ER-a containing breast cancer cells divide in response to estradiol. This question is still unanswered but there is evidence that one of the changes in breast cancer involves induction of other growth factor receptors (Ethier, 1995; Lippman and Dickson, 1990) . ERa may suppress the expression of certain growth factor receptors in normal mammary epithelium. Upon estradiol withdrawal, as occurs during menopause, growth factor receptors are expressed in ERa positive cells. Once this has occurred, ER-a can be activated not only by estradiol but also by growth factorstimulated tyrosine kinases (El Ashry et al., 1997; Marsh et al., 1999; Pietras et al., 1995) and the normal regulation of cell growth is lost. This scenario does neither explain the fact that prolonged exposure to estrogens (early menarche, late menopause, usage of hormone replacement therapy) is associated with increased breast cancer risk nor do the chemopreventive properties of antiestrogens fit into this model. It is therefore intriguing to speculate whether dysregulation of ER-a and PR expression are involved in breast carcinogenesis. If expression of ER-a is necessary in the normal breast epithelium to protect the cells from aberrantly expressing growth factor receptors, suppression of ER-a might undermine this protective mechanism. DNA methylation of the promoter region and the first exon appear to play a role in inactivating the ER-a and PR (Lapidus et al., 1996 (Lapidus et al., , 1998 Ottaviano et al., 1994) and treating cells with demethylating agents and/or HDAC inhibitors can restore ER-a expression (Yang et al., 2000 (Yang et al., , 2001b . There is a discrepancy concerning whether methylation of the ER-a CpG island is associated with the estrogen receptor status in vivo (Falette et al., 1990; Hori et al., 1999; Iwase et al., 1999; Kay et al., 1998; Lapidus et al., 1998) . So far it has not been possible to clarify whether DNA methylation of genes coding for steroid receptors is an initiating or an early event in breast carcinogenesis or whether it occurs later.
The functions of the recently discovered second ER, the ERb, in the breast remain to be defined but from what we have learned about its activities in in vitro systems, this estrogen receptor may have a protective role in the breast . Studies in human and rodent mammary glands as well as in human breast cancer biopsies revealed that ERb is by far the more abundant of the two ERs. Studies of the mammary glands of ERb knockout mice revealed abnormal epithelial growth, overexpression of Ki67 and severe cystic gland disease as mice age . In prostate cancer it has been shown that expression of ERb can be silenced by DNA methylation (Nojima et al., 2001) . Our own preliminary, unpublished data has demonstrated that ERb methylation is a common event in breast cancer as well.
The gene for the PR encodes two isoforms, PR-A and PR-B, which differ in both their N-terminal sequences and biological activities. The PR-B transcript is preferentially induced by ER while the PR-A is not. Since ligand-bound ER is a major transcriptional activator of PR-B gene expression, the presence of PR is indicative of functional ER. PR gene methylation has been demonstrated in about 40% of PR-negative breast tumors and several PR-negative breast cancer cell lines (Lapidus et al., 1996) .
Signal transducers and activators of transcription (STATs) are transcription factors activated in response to cytokines and growth factors. Constitutively active STAT3 has been shown to mediate oncogenic transformation in cultured cells and induce tumor formation in mice. A number of tumor-derived cell lines as well as samples from human cancer have been reported to constitutively express active STAT3 protein (Garcia et al., 2001) . Inhibition of the STAT3 signaling pathway using the Janus Kinase-selective inhibitor, AG490, and a dominant negative STAT3 (STAT3b) significantly suppresses the growth of ovarian and breast cancer cell lines harboring constitutively active STAT3. This also induced significant apoptosis in ovarian and breast cancer cell lines expressing high levels of constitutively active STAT3 but had a less profound effect on normal cells lacking constitutively active STAT3 (Burke et al., 2001) . It has been well documented that either GH or its downstream effector IGF-I stimulates primate mammary epithelial proliferation in vivo (Ng et al., 1997) and that these factors at least in part act by activating STAT3 (Gronowski et al., 1995) . STAT3 activity is regulated by a negative feedback loop in which activated STAT3 stimulates transcription of various genes including Suppressor of Cytokine Signaling (SOCS) 1. SOCS1 suppresses the JAK/STAT pathway by inhibiting JAK2 activity (Kishimoto and Kikutani, 2001 ). In mice, SOCS1 plays a role as a negative regulator of prolactin signaling and suggesting that SOCS1 is required for the prevention of lactation prior to parturition (Lindeman et al., 2001) . Recently it was demonstrated that SOCS1 was aberrantly methylated and silenced in human primary hepatocellular carcinoma (Yoshikawa et al., 2001) . The restoration of SOCS1 suppressed both growth rate and anchorage-independent growth of cells in which SOCS1 was methylation-silenced and JAK2 was constitutively activated. This growth suppression was caused by apoptosis and was reproduced by AG490, a specific chemical JAK2 inhibitor that reversed the constitutive phosphorylation of STAT3 in SOCS1 inactivated cells. Our own unpublished data demonstrate SOCS1 methylation in a considerable percentage of breast cancers.
The Ras superfamily of GTPases act as important regulatory switches to coordinate extracellular stimuli with activation of intracellular signaling pathways and appropriate biological responses. In breast cancer, the signaling pathways involving these GTPases may be upregulated due to increased coupling to growth factor receptors or other tyrosine kinases commonly overexpressed in this disease, increased expression of regulators, the Ras protein itself, or downstream effectors. Functional studies utilizing both in vitro and in vivo models demonstrated that Ras signaling can regulate a variety of endpoints relevant to breast cancer progression, including anchorage dependent and independent growth, tumorigenesis, steroid sensitivity and invasion (Malaney and Daly, 2001) . Although activated Ras proteins are usually associated with driving growth and transformation, they may also induce senescence, apoptosis, and terminal differentiation. The subversion of these anti-neoplastic effects during Ras-dependent tumor development may be as important as the acquisition of the pro-neoplastic effects. It has been shown that RASSF1 (RAS association family 1 gene) C binds Ras in a GTPdependent manner, both in vivo and directly in vitro. Moreover, activated Ras enhances, and dominant negative Ras inhibits, the cell death induced by transient transfection of RASSF1C (Vos et al., 2000) . Recent data support a role of RASSF1A in the proapoptotic pathway (Khokhlatchev et al., 2002) .
RASSF1A is methylated and silenced in about 62% of primary breast cancers irrespective of grade including grade I tumors, indicating that RASSF1A methylation might be an early event during breast cancer pathogenesis (Dammann et al., 2001) . Interestingly, RASSF1A methylation was found in 7.5% of normal tissues.
SYK is a protein tyrosine kinase that is widely expressed in hematopoietic cells. It has been shown that SYK is commonly expressed in normal human breast tissue, benign breast lesions and low-tumorigenic breast cancer cell lines. However, SYK is expressed at low or undetectable levels in invasive breast carcinoma tissue and cell lines. Transfection of wild-type SYK into a SYK-negative breast cancer cell line markedly inhibited its tumor growth and metastasis formation in athymic mice. Conversely, overexpression of a kinasedeficient SYK in a SYK-positive breast cancer cell line significantly increased its tumorigenicity and growth. Suppression of tumor growth by the reintroduction of SYK appeared to be the result of aberrant mitosis and cytokinesis (Coopman et al., 2000) . SYK 5' CpG hypermethylation has been detected in six out of 20 breast cancer cell lines, and the aberrant methylation status was strongly associated with loss of SYK gene expression and could be reverted upon treatment of cells with a methylation inhibitor. SYK was also hypermethylated in 32% of unselected breast tumors, whereas all of the matched neighboring normal breast tissues were methylation free (Yuan et al., 2001) .
(3) Insensitivity to growth-inhibitory signals
Transforming growth factor b (TGFb) acts in a number of ways (most still elusive) to prevent the phosphorylation that inactivates pRb. In this fashion, TGFb blocks advances through the G1 phase of the cell cycle (Hanahan and Weinberg, 2000) . The pRb signaling circuit, as governed by TGFb, can be disrupted in a variety of different ways: Suppression of type II TGFb receptor by overexpressing a dominant-negative mutant II TGFb receptor enhanced tumorigenesis in the mammary gland in response to carcinogen (Bottinger et al., 1997) . Breast cancer cell lines that express the estrogen receptor are refractory to TGF-b effects, whereas estrogen receptor-negative cells are often TGFb sensitive (Arteaga et al., 1988) . Loss or undetectable expression of type II receptor has been reported to contribute to TGFb resistance in ER + breast cancer cells (Kalkhoven et al., 1995; Sun et al., 1994) . Treatment of ER positive breast cancer cells with the DNA methyltransferase inhibitor 5-aza-CdR leads to accumulation of type II TGFb receptor transcripts and protein (Ammanamanchi et al., 1998) . Our unpublished data demonstrate type II TGFb receptor methylation in a subset of breast cancer specimens.
Using serial analysis of gene expression (SAGE) to compare the gene expression profiles of normal and ductal carcinoma in situ (DCIS) mammary epithelial cells, HIN-1 (high in normal-1) was identified (Krop et al., 2001) . HIN-1 expression is significantly down-regulated in 94% of human breast carcinomas and in 95% of preinvasive lesions, such as ductal and lobular carcinoma in situ. This decrease in HIN-1 expression is accompanied by hypermethylation of its promoter in the majority of breast cancer cell lines (490%) and primary tumors (74%). HIN-1 is a putative cytokine with no significant homology to known proteins. Reintroduction of HIN-1 into breast cancer cells inhibits cell growth. These results indicate that HIN-1 is a candidate tumor suppressor gene that is inactivated at high frequency in the earliest stages of breast tumorigenesis (Krop et al., 2001) .
Using differential display PCR, a gene called NOEY2 (ARHI) has been identified (Yu et al., 1999) . This gene has high homology to ras and rap and is expressed consistently in normal ovarian and breast epithelial cells but not in ovarian and breast cancers (Yu et al., 1999) . Expression of NOEY2 through transfection suppressed clonogenic growth of breast and ovarian cancer cells. Growth suppression was associated with down-regulation of the cyclin D1 promoter activity and induction of p21 WAF1/CIP1 . In an effort to identify mechanisms leading to NOEY2 silencing in cancer it was demonstrate that this gene is expressed monoallelically and is imprinted maternally. Loss of heterozygosity of the gene was detected in 41% of ovarian and breast cancers. In most of the cancer samples with loss of heterozygosity, the nonimprinted functional allele was deleted. Southern blot analysis demonstrated hypermethylation in two out of eight breast cancer cell lines (Yu et al., 1999) .
Another gene which is expressed in normal mammary epithelial cells but dramatically decreased in breast cancer cell lines is the normal epithelial cell-specific-1 (NES1)/kallikrein 10 ( Dhar et al., 2001) . Although the function of this gene has not yet been clarified, stable expression of NES1 in the NES1-negative MDA-MB-231 breast cancer cell line suppressed the oncogenicity as revealed by inhibition of the anchorage-independent growth and tumor formation in nude mice (Goyal et al., 1998) . Recently a strong correlation between exon 3 hypermethylation and loss of NES1 mRNA expression in a panel of breast cancer cell lines and in primary tumors has been described (Li et al., 2001b) . Treatment of NES1-nonexpressing cells with a demethylating agent led to reexpression of NES1, suggesting an important role of hypermethylation in the loss of NES1 expression (Li et al., 2001b) .
Beside physiological growth inhibitors, a variety of pharmacological substances also mediate growth suppression. For instance methotrexate (MTX) is part of combination chemotherapy regimens used in the treatment of various malignancies, including acute lymphoblastic leukemia, non-Hodgkin's lymphoma, osteosarcoma, and breast cancer (Bertino, 1993) . The major route for cellular uptake of MTX involves the reduced folate carrier (RFC), a bidirectional anion transporter with high affinity for reduced folates and antifolates but low affinity for folic acid (Sirotnak and Tolner, 1999) . Transport studies in in vitro models, have shown that down-regulation of RFC activity results in transport-mediated MTX resistance in breast cancer cell lines (Moscow et al., 1995) . Transfection of MDA-MB-231 breast cancer cells with RFC cDNA restored methotrexate uptake and increased methotrexate sensitivity by approximately 50-fold. A CpG island in the promoter region of RFC was found to be methylated in MDA-MB-231 cells, but was unmethylated in RFC expressing, methotrexate-sensitive MCF-7 breast cancer cells. Treatment of MDA-MB-231 cells with 5-aza-CdR restored RFC expression (Worm et al., 2001) .
(4) Evasion of programmed cell death p53 has emerged as one of the leaders among the multitude of players involved in apoptosis due to its ability to selective induce apoptosis in stressed or abnormal cells, thereby protecting the organism from cancer development (reviewed in Vousden, 2000) . Therefore p53 function is thought to be controlled by several mechanisms, one of the most effective being regulation of protein stability. MDM2 is an E3 ligase that targets both p53 and itself for ubiquitination. MDM2 is a transcriptional target of p53, creating a negative feedback loop where p53 activates expression of MDM2, which keeps p53 levels low during normal conditions. DNA damage, oncogene activation, telomere erosion and hypoxia inhibit MDM2 and thereby stabilize p53. Oncogenes like myc and ras can induce stabilization of p53 by enlisting the activity of ARF, a protein that functions by binding directly to MDM2, inhibiting the ubiquitination of p53 and allowing accumulation of p53 in the nucleus. ARF expression can be directly regulated by transcription factors DMP1 and E2F1 or by DAP kinase, or downregulated by factors such as Twist and Bmi1. Beside control of p53 degradation, HOXA5 regulates synthesis of p53 by binding and activating consensus HOX binding sites in the p53 promoter (Raman et al., 2000) . Both major apoptotic pathways -via death receptor signaling or mitochondrial perturbations, including cytochrome c release, activation of APAF-1 and subsequently activating caspases -can be mediated by p53.
Inactivation of p53 by mutations is not that common in human breast cancer and is seen in about 20% of tumors (Pharoah et al., 1999) . p53 mRNA levels are 5 -10-fold lower in breast cancer cell lines than in normal breast epithelium (Raman et al., 2000) . Breast cancer cell lines and breast cancer specimens display a coordinate loss of p53 and HOXA5 mRNA and protein expression. The HOXA5 promoter region was methylated in 16 out of 20 p53-negative breast tumor specimens but unmethylated in human mammary epithelial cells with a finite lifespan as well as in immortalized HMECs. DNMT inhibitors restored expression of HOXA5 (Raman et al., 2000) .
Some genes involved in p53 protein stability have also been shown to be regulated by DNA-methylation. DAP kinase has been reported to be methylated in 7% of breast cancers . Twist was shown to be methylated in 21 out of 50 invasive and four out of 14 in situ breast cancers . Expression of downstream members of the p53 pathway like caspase-8 (Fulda et al., 2001) or Apaf1 (Soengas et al., 2001) have been shown to be directly or indirectly altered by DNA methylation.
TMS1 (target of methylation-induced silencing) belongs to a family of apoptotic signaling molecules that contain a CARD (caspase recruitment domain). TMS1 is likely to function as an adaptor protein, acting in the initiation phase of an apoptotic pathway by coupling death receptors at the cell surface, or intrinsic death signals, to the activation of the caspase cascade.
TMS1 is aberrantly methylated and silenced in human breast cancer cells and aberrant methylation of TMS1 was evident in 40% (11 out of 27) of primary breast tumors analysed. Ectopic expression of TMS1 induced apoptosis in human embryonic kidney cells and inhibited the survival of human breast cancer cells (Conway et al., 2000) .
ZAC, a new zinc finger protein was named according to its functional properties, namely induction of apoptosis and control of cell cycle progression. ZAC is expressed in normal mammary gland and maps to 6q24-q25, a recognized hot spot for deletion on 6q in breast cancer. A survey of eight breast cancer cell lines showed either a deeply reduced or complete loss of ZAC expression. Treatment of three of these cell lines with the methylation-interfering agent 5-aza-CdR induced ZAC re-expression. In addition, Northern blot and RNase protection assay analysis of ZAC expression in 23 unselected primary breast tumors indicated a reduced expression in several samples (Bilanges et al., 1999) .
Another gene, Glypican 3 (GPC3), a membranebound heparan sulfate proteoglycan that is mutated in the Simpson-Golabi-Behmel syndrome, was also shown to induce apoptosis in breast cancer (Gonzalez et al., 1998) . GPC3 expression is also silenced in human breast cancer, and this silencing is due, at least in part, to hypermethylation of the GPC3 promoter. Although the exact function of the gene is not yet known, it was demonstrated that ectopic expression of GPC3 inhibited growth in eight out of 10 breast cancer cell lines (Xiang et al., 2001) .
FHIT, a diadenosine hydrolase may be involved in growth control pathways of the cell. Studies on protein-protein interactions, cell lines, including tumorigenicity tests, and knockout mice suggest that the FHIT protein is involved in cell proliferation and apoptosis, and might act as a tumor suppressor. In several different cancers, including breast cancer, alterations in the FHIT gene have been detected in high frequency (Ingvarsson, 2001) . 5' CpG island methylation of the FHIT gene has been detected frequently in breast cancer and correlated with loss of gene expression (Zochbauer-Muller et al., 2001 ). THBS1 (Thrombospondin-1) binds to CD36, a transmembrane receptor on endothelial cells coupled to intracellular Src-like tyrosine kinases (Bull et al., 1994) and is a prototypical angiogenesis inhibitor. THBS1 has been shown to be positively regulated by the p53 tumor suppressor protein and consequently, loss of p53 function (as outlined above) leads to THBS1 decrease, liberating endothelial cells from inhibitory effects (Dameron et al., 1994) . To ascertain the participation of the THBS1 in tumor progression, mammary tumor-prone mice that either lack or specifically overexpress THBS1 in the mammary gland have been generated (Rodriguez-Manzaneque et al., 2001) . Tumor burden and vasculature were significantly increased in THBS1-deficient animals, and capillaries within the tumor appeared distended and sinusoidal. In contrast, THBS1 overexpressors showed delayed tumor growth or lacked frank tumor development. Absence of THBS1 resulted in an increased association of VEGF with its receptor and higher levels of active matrix metalloproteinase-9 (MMP9), a molecule previously shown to facilitate both angiogenesis and tumor invasion. Enzymatic activation of proMMP9 was suppressed by THBS1 in vitro (Rodriguez-Manzaneque et al., 2001). Besides regulation due to p53, de novo methylation may serve as a potential way to inactivate THBS1 expression in human neoplasms . p73 inhibits expression of VEGF (Salimath et al, 2000) and DNA methylation causes its suppression in lymphoid leukemia cells . In breast cancer p73 methylation has not been studied properly.
Maspin, a unique member of the serpin family, is a secreted protein whose downregulation is associated with the development of breast cancers (Zou et al., 1994) . Maspin is an effective inhibitor of angiogenesis. It was shown to act directly on cultured endothelial cells to stop their migration towards bFGF and VEGF and to limit mitogenesis and tube formation. It blocked neovascularization in the rat cornea pocket model (Zhang et al., 2000) . HMECs expressed maspin mRNA and displayed a completely non-methylated maspin gene promoter with an open chromatin structure. In contrast, seven of nine breast cancer cell lines had no detectable maspin expression and six of these seven maspin-negative breast cancer cell lines also displayed an aberrant pattern of cytosine methylation of the maspin promoter. Moreover, maspin gene expression was re-activated in MCF-7 cells by treatment with a DNA demethylating agent (Domann et al., 2000) .
(6) Tissue invasion and metastasis
Invasion and metastasis involves changes in the physical coupling of cells to their microenvironment and activation of extracellular proteases. Epithelial cells maintain contact with their neighbors through adherens junctions. Cadherins traverse the membrane, associating with cadherins on adjacent cells. ECadherin (E-Cad), suppresses tumor cell invasion and metastasis in experimental tumor models. Decreased ECad expression is common in poorly differentiated, advanced-stage carcinomas. The 5' CpG island of ECad is densely methylated in E-Cad-negative breast carcinoma cell lines and primary breast carcinoma tissue but is unmethylated in normal breast tissue. The treatment with 5-aza-CdR, partially restored E-Cad RNA and protein levels in E-Cad-negative breast carcinoma cell lines (Graff et al., 2000) .
Expression of a second cadherin, H-cadherin (CDH13), was shown to be significantly reduced in human breast carcinoma cell lines and breast cancer specimens. Introduction of CDH13 cDNA markedly diminished tumor cell growth and resulted in a significant change from invasive morphology to a normal cell-like morphology in the Matrigel outgrowth assay (Lee, 1996) . Methylation of CDH13 has frequently been observed in primary breast tumors (18 out of 55, 33%) and cell lines (seven out of 20, 35%). Gene expression was restored in methylated cell lines tested after treatment with 5-aza-CdR (Toyooka et al., 2001) .
On the cytoplasmic face, b-catenin connects to the cadherin tail and associates with a-catenin, which in turn binds to actin. Accumulation of b-Catenin occurs in the absence of APC (adenomatous polyposis coli) and might lead to activation of c-myc and cyclin D1 (reviewed in Fearnhead et al., 2001 ). In addition, APC is involved in signal transduction, stabilization of the cytoskeleton and regulation of cell cycle and apoptosis (Fearnhead et al., 2001) . The APC promoter 1A was methylated in 34 out of 77 breast cancer tumors and cell lines (44%). There was complete concordance between promoter methylation and silencing of its transcript in cell lines. Demethylation with 5-aza-CdR treatment restored transcript 1A expression in all eight methylated cell lines tested . found methylation of the APC promoter CpG island in 18 out of 50 (36%) primary breast cancers and in none of 21 non-cancerous breast tissue samples.
Prostasin is a serine protease, which decreases invasiveness in vitro . Prostasin mRNA and protein were shown to be expressed in normal HMECs, the poorly invasive breast carcinoma cell line MCF-7 and the nonmetastatic breast carcinoma cell line MDA-MB-453, but absent in highly invasive and metastatic breast carcinoma cell lines MDA-MB-231 and MDA-MB-435s. Enforced reexpression of prostasin in MDA-MB-231 and MDA-MB435s reduced the in vitro invasiveness of either cell line by 50%. Examination of the prostasin gene promoter and first exon revealed a GC-enriched region that contains transcription regulatory elements. The promoter and exon 1 region of the prostasin gene was investigated for DNA methylation in HMEC and the carcinoma cell lines. The results revealed a methylation pattern that correlates with prostasin expression in these cells.
Demethylation coupled with histone deacetylase inhibition resulted in reactivated expression of the prostasin mRNA in MDA-MB-231 and MDA-MB435s cells (Chen and Chai, 2002) . Tissue inhibitor of metalloproteinase-3 (TIMP-3) antagonizes matrix metalloproteinase activity and can suppress tumor growth, angiogenesis, invasion, and metastasis (Uria et al., 1994) . The TIMP-3 promoter is methylated in about 30% of human breast cancer cell lines and primary breast tumors and TIMP-3 expression was restored after 5-aza-CdR-mediated demethylation of the TIMP-3 proximal promoter region (Bachman et al., 1999) .
The nm23 gene family exhibits metastasis suppressor activity in breast cancer in vivo (Leone et al., 1993) and low nm23-H1 expression was a significant predictor of poor survival in univariate and multivariate analyses (Heimann et al., 1998) . Two CpG islands are present in the nm23-H1 promoter and bisulfite sequencing of these CpG islands in a panel of cell lines and in 20 infiltrating ductal carcinomas revealed that one island exhibited infrequent differential methylation.
Treatment with 5-aza-CdR, increased the nm23-H1 expression of five of 11 human breast carcinoma cell lines in vitro, including three of three metastatically competent lines. Increased nm23-H1 expression was accompanied by a reduction in motility in vitro, with minimal effect on proliferation (Hartsough et al., 2001) .
Overexpression of Breast Cancer Specific Gene 1 (BCSG1) in breast cancer cells leads to a significant increase in motility and invasiveness in vitro and a profound augmentation of metastasis in vivo (Jia et al., 1999) . BCSG1 is not expressed in normal breast tissues but highly expressed in advanced infiltrating breast carcinomas. A recent publication demonstrated that BCSG1 might be regulated by methylation and that treatment with demethylating agents activated BCSG1 transcription (Lu et al., 2001) . It has not yet been demonstrated whether treatment with demethylating agents causes more aggressive cancers.
Timing of DNA methylation in breast carcinogenesis
We propose that DNA methylation and silencing of certain genes (Figure 1 ) might support clonal selection due to growth advantages. However, there are certain genes which do not support this theory in that there is no obvious selection advantage to their inactivation.
p16 inactivation is mandatory for immortalization of HMECs (Kiyono et al., 1998) and p16 silencing in these cells is mediated by DNA methylation (Brenner et al., 1998; Foster et al., 1998; Huschtscha et al., 1998) . But this specific p16 promoter region is very rarely methylated in breast cancer (Lehmann et al., 2002) . Unexpectedly, high p16
INK4A mRNA expression was associated with high tumor grade (P=0.006), 54 axillary lymph node involvement (P=0.004), ER negativity (P=0.0001), and increased risk of relapse (P=0.006) (Hui et al., 2000) . These conflicting results imply that p16 methylation might be needed to overcome senescence as an initiating event in breast carcinogenesis. Once immortalization has been reached, these cells may establish a microenvironment enabling other cells -without p16 methylation -to progress towards cancer. Passive demethylation later on in breast carcinogenesis by inhibiting DNMT1 binding to the p16 promoter may serve as an alternative explanation for this phenomenon.
Expression of genes like COX-2 (Ristimaki et al., 2002) , BCSG1 (Lu et al., 2001) or Gelsolin (Thor et al., 2001) are associated with poor prognostic parameters in breast cancer but on the other hand are frequently methylated (unpublished data; Lu et al., 2001; Mielnicki et al., 1999) . These genes probably become methylated 'by chance' during carcinogenesis by mechanisms (probably gene silencing) responsible for the methylation of the majority of the other genes.
Carcinogenesis is a highly complex process in which interactions between epithelial and stromal cells (Krtolica et al., 2001) , paracrine, endocrine, as well as autocrine mechanisms are all involved in this process Krtolica et al., 2001; Moinfar et al, 2000) .
DNA methylation, memory and breast carcinogenesis
Several lines of evidence suggest that DNA methylation does not intervene to silence active promoters, but effects genes that are already silent (reviewed in Bird, 2002) . The signal for this putative gene silencingrelated de novo methylation is unknown, but the possibility that chromatin states recruit the DNA methylation machinery to a particular DNA sequence is attractive (Selker, 1990) . The acetylation and methylation state of nucleosomal histones is tightly correlated with transcriptional activity (Jenuwein and Allis, 2001) . In Neurospora, an intimate link between histone methylation and DNA methylation has been described (Tamaru and Selker, 2001 ). Methylation of already silenced genes may occur to silence them irrevocably. X inactivation and silencing of transposable elements are two examples (Bird, 2002; Heard et al., 2001) . On the other hand, transcriptionally active chromatin might protect against DNA methylation at CpG islands. Promoter activity early in development may create a methylation-free CpG island; in other words, unmethylated CpG islands might be footprints of embryonic promoter activity (Bird, 2002) . Indeed, a CpG-island promoter whose product RNA is not expected to occur in the early embryo (a-globin, 68k neurofilament) is nevertheless expressed, whereas transcripts from a CpG-deficient promoter (b-globin, opsin, casein) are not detected (Daniels et al., 1997; Macleod et al., 1998) . Recent studies in human prostate cancer cells support this hypothesis: a combination of prior gene silencing and random 'seeds' of methylation trigger hypermethylation of the GSTP1 gene (Song et al., 2002) .
DNA methylation is an important mechanism contributing to epigenetic mechanisms (Bird, 2002; Jones and Laird, 1999) . Epigenetics can explain mitotically and/or meiotically heritable changes in gene function that cannot be explained by changes in DNA. The heritability of methylation states and the secondary nature of the decision to invite or exclude methylation support the idea that DNA methylation is adapted for a specific cellular memory function in development (Bird, 2002) .
By studying the tyrosine aminotransferase (Tat) gene in fetal rat hepatocytes as well as rat hepatoma cells, a mechanism for memorizing hormone action has been described . Glucocorticoids regulate DNA demethylation within a key enhancer of the rat liver-specific Tat gene and additional DNAassociated factors are subsequently recruited. Demethylation persists after the wave of expression has subsided, and reinduction of the silent gene by further hormone treatment is significantly stronger as a result. This system provides a model for a DNA methylationmediated memory of the first hormone induction (Kress et al., 2001) .
Most of the data supporting the 'memory-function' of DNA methylation pattern stem from embryogenesis. So far there is indirect evidence that this mechanism holds true for carcinogenesis. As outlined above there are genes according to certain pathways, which are switched on during senescence of HMECs (e.g. p16, RAR-b2, STAT-1 and other interferon regulated genes, mac25, etc.). DNA methylation and permanent silencing is frequently observed within these genes after HMECs have become immortal and in breast cancer cell lines and in breast cancer specimens.
On the other hand, evidence is now accumulating that some of these methylation changes may initiate in subpopulations of normal cells as a function of age and progressively increase during carcinogenesis. Agerelated methylation appears to be widespread and is one of the earliest changes marking the risk for neoplasia (Ahuja et al., 1998) . Age-related methylation involves at least 50% of the genes which are hypermethylated in colon cancer, and it was proposed that such age-related methylation may partly account for the fact that most cancers occur as a function of increased age (Ahuja and Issa, 2000) . Although DNA methylation has not been studied in terms of age in non-neoplastic breast tissue, an age related increase in ERa gene methylation was demonstrated in the right atrium of the heart (Post et al., 1999) as well as in the colon (Ahuja and Issa, 2000) . DNA methylation was also used as a tag to characterize stem cells that maintain human colon crypts (Yatabe et al., 2001) . Thereby methylation was shown to increase with aging but varied between crypts and was mosaic within single crypts.
Premalignant breast lesions are thought to arise primarily from stem cells in normal terminal duct lobular units (TDLUs) (Rudland, 1993) . In normal TDLUs a low rate of proliferation has been reported averaging only about 2% (Ferguson and Anderson, 1981; Going et al, 1988; Kamel et al., 1989; Longacre and Bartow, 1986; Meyer, 1977) . In premenopausal women, the rate fluctuates and is approximately twice as high in the luteal as in the follicular phase of the menstrual cycle (Ferguson and Anderson, 1981; Going et al, 1988; Longacre and Bartow, 1986; Meyer, 1977) , whereas in postmenopausal women, the proliferation rate is somewhat lower and relatively stable (Lelle et al., 1987; Meyer and Connor, 1982) .
We hypothesize that DNA methylation contributes to silence specific genes in some stem cells in TDLUs due to their lack of expression (Bird, 2002) . These methylation changes may not be detectable in young individuals due to the large background of unmethylated CpG islands, but may accumulate as a function of age. In vitro some HMECs -after having methylated and therefore irrevocably suppressed p16 -escape senescence , most likely due to a selection benefit.
Methylation of various genes, not needed in quiescent breast stem cells may also accumulate in vivo. Stimuli like exposure to endogenous and exogenous estrogens might induce proliferation of these cells. Due to methylation and permanent silencing of genes needed for physiologic turnover and senescence, these cells are prone to become immortal. Breast cancer might then be a manifestation of the above mentioned six essential alterations in cell physiology -in part mediated by DNA methylation.
Prevention of breast cancer
Prevention of breast cancer can be achieved by a better understanding of the etiological factors contributing to the development of the disease. There is strong evidence that women who experience a full-term pregnancy early in their lives have a significantly reduced risk for developing breast cancer (Chodosh et al., 1999; MacMahon et al., 1970) . This was recapitulated in rat models that demonstrated that early full-term pregnancy confers resistance to chemical carcinogen-induced mammary tumorigenesis. This protection can be also mimicked with the hormones estrogen (E) and progesterone (P) or with human chorionic gonadotropin (Chodosh et al., 1999; Sivaraman et al., 2001 ; and references therein) given either before or after carcinogen challenge to induce a refractory state. An excellent study by Sivaraman et al. (2001) , described p53 to be a potential mediator of pregnancy-and hormone-induced resistance to mammary carcinogenesis. A striking increase in p53 and down-stream effectors in the rat mammary gland was observed after E/P-treatment compared with untreated age matched virgin rats. These changes in turn dictate the proliferative response to carcinogen challenge and include a block in carcinogen-induced increase in mammary epithelial cell proliferation and an increased and sustained expression of nuclear p53 in the hormone-treated mammary gland. This hormoneinduced nuclear p53 is transcriptionally active as evidenced by increased expression of mdm2 and p21 (CIP1/WAF1). Importantly, exposure to perphenazine (a compound that induces mammary gland differentiation but does not confer protection) does not induce p53 expression, indicating that p53 is not a marker of differentiation. The proliferative block and induction of p53 are operative in both rats and mice, which supports the generality of the proposed hypothesis (Sivaraman et al., 2001) . Using an analogous approach, RbAp46 has also been shown to be persistently upregulated after E/P-treatment (Ginger et al., 2001) . This protein interacts with BRCA1, interacts directly with histones H3 and H4 and is a component of multisubunit complexes that are involved in histone deacetylation, histone acetylation, nucleosome disruption and nucleosome assembly (reviewed in Ginger et al., 2001 ). Using another model system, Boulanger and Smith (2001) were able to demonstrate that premature stem cell senescence may also reduce mammary cancer risk.
These results may suggest that during development and differentiation, early inductive processes that influence cell fate at a later stage may leave marks at distinct gene loci that are maintained through several rounds of mitosis. DNA methylation is part of this epigenetic memory that restricts or permits differential expression of genes in descendant cells. This can result in establishment of a cell-type-specific DNA methylation pattern that may restrict the ability to transcribe genes needed for apoptosis, senescence and other physiological processes in some cells. These cells may be predestined to immortalization and de-differentiation, and become precursors of neoplastic cells. In other words, events that switch on pathways (and therefore prevent methylation of genes involved) in normal cells needed for physiological turnover, might prevent these pathways from becoming irrevocably switched off by methylation.
Beside early age at first pregnancy, there are two other pregnancy-associated breast cancer risk reducing factors. Evidence suggests that immune, hormonal, or genetic mechanisms that induce hypertension or preeclampsia during pregnancy reduce the risk of breast cancer both in the mother (Polednak and Janerich, 1983; Thompson et al., 1989; Troisi et al., 1998) and in the daughter (Ekbom et al., 1992 (Ekbom et al., , 1997 . Secondly, independent reductions in the rate of subsequent breast cancer were associated with increases in blood pressure between the second and the third trimesters, infarctions in the maternal floor of the placenta, low placental weight, and small placental diameter (Cohn et al., 2001) .
Decreased perfusion of the placenta which is a prerequisite for development of preeclampsia and is associated with small placentas and maternal floor infarction of the placenta, causes generation of reactive oxygen species. Markers of oxidative stress have been detected in the blood of women with preeclampsia for over 40 years (Dekker and Sibai, 2001; Roberts and Cooper, 2001 ; and references therein). Reactive oxygen species have been demonstrated to induce p53 and senescence (Chen et al., 1998; Chen, 2000; Kinscherf et al., 1998; Krtolica et al., 2001; Sugano et al., 1995) .
It is tempting to speculate that in early life short term exposure to situations causing a challenge of p53 dependent pathways or other senescence-inducing pathways might prevent genes involved, from becoming irrevocably silenced by methylation. In other words HMECs might 'recall' the challenge their predecessors have experienced decades before and are therefore able to adequately respond to a carcinogenic stimulus.
DNA methylation as a tool for early detection of breast cancer
It is questionable whether screening for breast cancer by mammography reduces mortality (Miettinen et al., 2002; Olsen and Gotzsche, 2001 ). An alternative DNAbased approach for early detection of breast cancer might be promising since DNA extracted from patient's plasma, serum or other body fluids could be easily amplified by PCR technology and is therefore potentially more sensitive than conventional tests. RNA is not as useful as a detection marker because of its inherent instability. Detection of promoter CpG island hypermethylation offers several advantages compared to other DNA alterations in cancer (reviewed in Widschwendter and Jones, 2002) . Methylated DNA can be detected with a very high degree of specificity, even in the presence of a vast excess of unmethylated DNA. MethyLight technology for instance can detect a single hypermethylated allele against a background of 10 000 unmethylated alleles (Eads et al., 2000) . Methylated DNA from patients with manifest breast cancer has been detected in blood (Silva et al., 1999a,b) as well as in ductal lavage fluid . Detection of DNA methylation in patients' blood might prove to be useful as a predictive marker at the moment of primary diagnosis or as a marker for early detection of relapse of disease. As the aim is to detect cancer early or even noninvasive or premalignant lesions, fluid collected from the breasts may be a very promising substrate. It will take a long time to realize the aim to reduce the burden of diseases within the population due to screening based on these first results. As we have reached Phase II (according to suggestions by Sullivan et al. (2001) ) there are many questions to answer before a retrospective longitudinal study (Phase III) will be conducted: which genes should be analysed? Which method should be used? For instance, a gene which is methylated with high prevalence in aggressive cancer might be unmethylated in a non-invasive cancer and vice versa.
DNA methylation as a target for new preventive and therapeutic approaches
The accumulated knowledge offers promising new preventive and therapeutic strategies. Challenging breast epithelial stem cells for a short period of time (analogous to pregnancy at early age or pregnancies with placental pathologies) might prevent cells from permanently switching off genes which would be needed later in life to resist carcinogenic triggers. Classes of agents currently undergoing evaluation in clinical prevention trials or those for which testing is planned in the near future include new selective estrogen receptor modulators, aromatase inactivators/ inhibitors, gonadotrophin-releasing hormone agonists, monoterpenes, isoflavones, retinoids, rexinoids, vitamin D derivatives, and inhibitors of tyrosine kinase, cyclooxygenase-2, and polyamine synthesis (reviewed in Fabian, 2001 ). Most of these substances have shown to be directly or indirectly involved in the above mentioned six novel capabilities needed for development of breast cancer. Whether they will have an impact on 'preventing DNA methylation' remains to be elucidated.
Once a gene has been silenced by histone deacetylation (HDACs), the use of HDAC inhibitors, such as suberoylanilide hydroxamic acid (SAHA) might be a promising way to reinduce expression. In breast cancer cell lines SAHA causes the inhibition of proliferation, accumulation of cells in a dose-dependent manner in G(1) then G(2)-M phase of the cell cycle, and induction of differentiation (Munster et al., 2001) . SAHA and other HDAC inhibitors are currently in Phase I clinical trials.
Finally, genes that have already been methylated can be demethylated and reexpressed as outlined above. Demethylating chemopreventive strategies have been shown in vivo to be effective (Laird et al., 1995; Ramchandani et al., 1997) . 5-aza-CdR has already been tested in a phase II study in elderly patients with high-risk myelodysplastic syndrome (Wijermans et al., 2000) . However systemic treatment with this drug commonly causes myelosuppression. It remains to be tested whether intraductal, retrograde application of various substances (possibly combined with systemic treatment) might be another chemopreventive approach.
DNA-methylation is a very effective strategy to irrevocably switching off certain genes. Cells which have accumulated DNA-methylation of promoter regions of genes which would be needed to adequately respond to carcinogenic stimuli, are prone to become tumor cells. Future research might prove whether this knowledge translates into strategies for early detection or even prevention of breast cancer.
